ESMO 2017 Industry Satellite Symposium

Scientific programme

Therapeutic options for the patient beyond 2nd line in mCRC

Chairpersons:
A. Falcone (Italy)
A. Carrato (Spain)

Introduction
A. Carrato (Spain)

Optimal treatment sequencing in mCRC
D. Arnold (Portugal)

The clinical value of treatment beyond 2nd line for the patient
A. Stein (Germany)

The importance of patient involvement in treatment decisions
- Perspective of an onco-psychiatrist
S. Dolbeault (France)
- Perspective of a medical oncologist
H. Wasan (UK)

Discussion and meeting close
A. Falcone (Italy)